Mirtazapina Flas Stada (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors while enhancing 5‑HT1 activity, and blocks H1 receptors, producing its antidepressant and sedative effects.

The appropriate dose of Mirtazapina Flas Stada is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment.

Mirtazapina Flas Stada is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but lacking well‑controlled human data. Use only if the potential benefit justifies the potential risk. It is excreted in breast milk; breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those prone to weight gain.

Store the tablets at room temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Mirtazapina Flas Stada is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe neutropenia, suicidal thoughts or behaviors (especially early in treatment), serotonin syndrome when combined with other serotonergic drugs, and significant hypotension. Patients should be monitored closely for any of these events.

Mirtazapina Flas Stada should be avoided in patients with known hypersensitivity to mirtazapine or any excipients, those currently taking MAO inhibitors, or individuals with severe hepatic impairment without medical supervision. Caution is also advised for the elderly due to increased sedation and fall risk.